Stay updated with breaking news from Diffuse Large Cell Lymphoma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Recent significant breakthroughs for diffuse large B-cell lymphoma (DLBCL) have come through the use of CAR T-cell and immunotherapies and the FDA approval of polatuzumab for frontline DLBCL.
The approval expands the indication to include use of the drug after the failure of first-line therapy.
The European body has recommended approval of a new CAR-T cell therapy, as well as two generic version of dasatinib and a biosimilar of pegfilgrastim.
Chemotherapy, the decades-old approach to second-line therapy for relapsed/refractory large B cell lymphomas, may soon be obsolete, investigators say.
Single-agent regimens are most likely not efficient enough to substantially improve the outcome of patients with diffuse large B-cell lymphoma (DLBCL).